NCT02357654

GnRH for Luteal Support in IVF/ICSI/FET Cycles

• Status: Recruiting
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 350 (estimated)
• Sponsor: University Reproductive Associates · Academic / Other
• Sex: Female
• Age: 18 Years – 40 Years
• Healthy volunteers: Not accepted

Summary

During IVF cycles an embryo is generally placed into the uterine cavity between 3 and 5 days after fertilization. For a successful pregnancy to take place, that embryo must then implant in the properly primed and staged endometrium, which subsequently must continue to develop to accommodate the growing and maturing embryo and then fetus. This process is normally regulated by hormonal interactions between the fetal, endometrial and luteal tissue. It has been found that after IVF additional support for the endometrium with progesterone improves implantation and subsequent live birth rates in IVF cycle . Recent data has shown that additional supplementation with a single administration of a GnRH agonist around the time the time of embryo transfer may further enhance these rates .

Detailed description

see above

Conditions

• Infertility

Interventions

Type	Name	Description
DRUG	GnRH	single shot of GnRH agonist
DRUG	placebo	placebo

Timeline

• Start date: 2015-11-01
• Primary completion: 2026-07-01
• Completion: 2026-07-01
• First posted: 2015-02-06
• Last updated: 2025-08-01

Locations

1 site across 1 country: United States